Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 241

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Arsenic Trioxide Rescues Structural p53 Mutations through a Cryptic Allosteric Site

Chen, Shuo, Wu, Jia-Le, Liang, Ying, Tang, Yi-Gang, Song, Hua-Xin, Wu, Li-Li, Xing, Yang-Fei, Yan, Ni, Li, Yun-Tong, Wang, Zheng-Yuan, Xiao, Shu-Jun, Lu, Xin, Chen, Sai-Juan, Lu, Min·2021·Cancer Cell
DOI 10.1016/j.ccell.2020.11.013
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ccell.2020.11.013

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

2 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Research works printed but not linked: 45

  1. Boeckler, 2008, Targeted rescue of a destabilized mutant of p53 by an in silico screened drug, Proc. Natl. Acad. Sci. U S A, 105, 10360, 10.1073/pnas.0805326105 · DOI · Paper page
  2. Bullock, 2001, Rescuing the function of mutant p53, Nat. Rev. Cancer, 1, 68, 10.1038/35094077 · DOI · Paper page
  3. Bullock, 2000, Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy, Oncogene, 19, 1245, 10.1038/sj.onc.1203434 · DOI · Paper page
  4. Chen, 1997, Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells, Blood, 89, 3345
  5. Chen, 1996, In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: as2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins, Blood, 88, 1052, 10.1182/blood.V88.3.1052.1052 · DOI · Paper page
  6. Chen, 2011, Structural and functional studies of LRP6 Ectodomain reveal a Platform for Wnt signaling, Dev. Cell, 21, 848, 10.1016/j.devcel.2011.09.007 · DOI
  7. Chen, 2019, iASPP mediates p53 selectivity through a modular mechanism fine-tuning DNA recognition, Proc. Natl. Acad. Sci. U S A, 116, 17470, 10.1073/pnas.1909393116 · DOI · Paper page
  8. de The, 2017, Acute promyelocytic leukemia: a paradigm for oncoprotein-targeted cure, Cancer Cell, 32, 552, 10.1016/j.ccell.2017.10.002 · DOI · Paper page
  9. Dobin, 2013, STAR: ultrafast universal RNA-seq aligner, Bioinformatics, 29, 15, 10.1093/bioinformatics/bts635 · DOI · Paper page
  10. Friedman, 1993, The p53 protein is an unusually shaped tetramer that binds directly to DNA, Proc. Natl. Acad. Sci. U S A, 90, 3319, 10.1073/pnas.90.8.3319 · DOI · Paper page
  11. Gannon, 1990, Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form, EMBO J., 9, 1595, 10.1002/j.1460-2075.1990.tb08279.x · DOI · Paper page
  12. Hu, 2009, Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia, Proc. Natl. Acad. Sci. U S A, 106, 3342, 10.1073/pnas.0813280106 · DOI · Paper page
  13. Hu, 2020, Arsenic trioxide potentiates Gilteritinib-induced apoptosis in FLT3-ITD positive leukemic cells via IRE1a-JNK-mediated endoplasmic reticulum stress, Cancer Cell Int., 20, 250, 10.1186/s12935-020-01341-5 · doi:10.1186/s12935-020-01341-5
  14. Hughes, 1999, Strain-dependent disposition of inorganic arsenic in the mouse, Toxicology, 137, 95, 10.1016/S0300-483X(99)00068-2 · doi:10.1016/s0300-483x(99)00068-2
  15. Jing, 2001, Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo, Blood, 97, 264, 10.1182/blood.V97.1.264 · DOI · Paper page
  16. Joerger, 2006, Structural basis for understanding oncogenic p53 mutations and designing rescue drugs, Proc. Natl. Acad. Sci. U S A, 103, 15056, 10.1073/pnas.0607286103 · DOI · Paper page
  17. Joerger, 2008, Structural biology of the tumor suppressor p53, Annu. Rev. Biochem., 77, 557, 10.1146/annurev.biochem.77.060806.091238 · DOI · Paper page
  18. Joerger, 2010, The tumor suppressor p53: from structures to drug discovery, Cold Spring Harb Perspect. Biol., 2, a000919, 10.1101/cshperspect.a000919 · DOI · Paper page
  19. Joerger, 2016, The p53 pathway: origins, inactivation in cancer, and emerging therapeutic approaches, Annu. Rev. Biochem., 85, 375, 10.1146/annurev-biochem-060815-014710 · DOI · Paper page
  20. Kandoth, 2013, Mutational landscape and significance across 12 major cancer types, Nature, 502, 333, 10.1038/nature12634 · DOI · Paper page
  21. Kitchin, 2006, Dissociation of arsenite-peptide complexes: triphasic nature, rate constants, half-lives, and biological importance, J. Biochem. Mol. Toxicol., 20, 48, 10.1002/jbt.20108 · DOI
  22. Krissinel, 2004, Secondary-structure matching (SSM), a new tool for fast protein structure alignment in three dimensions, Acta Crystallogr. D Biol. Crystallogr., 60, 2256, 10.1107/S0907444904026460 · DOI · Paper page
  23. Lallemand-Breitenbach, 1999, Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia, J. Exp. Med., 189, 1043, 10.1084/jem.189.7.1043 · DOI · Paper page
  24. Liu, 2003, Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL, Blood, 101, 4078, 10.1182/blood-2002-10-3231 · DOI · Paper page
  25. Lu, 2013, Restoring p53 function in human melanoma cells by inhibiting MDM2 and cyclin B1/CDK1-phosphorylated nuclear iASPP, Cancer cell, 23, 618, 10.1016/j.ccr.2013.03.013 · DOI
  26. Modi, 2005, Arsenic antagonism studies with monoisoamyl DMSA and zinc in male mice, Environ. Toxicol. Pharmacol., 19, 131, 10.1016/j.etap.2004.05.008 · DOI
  27. Nikolova, 1998, Semirational design of active tumor suppressor p53 DNA binding domain with enhanced stability, Proc. Natl. Acad. Sci. U S A, 95, 14675, 10.1073/pnas.95.25.14675 · DOI · Paper page
  28. Petty, 2011, An induced fit mechanism regulates p53 DNA binding kinetics to confer sequence specificity, EMBO J., 30, 2167, 10.1038/emboj.2011.127 · DOI · Paper page
  29. Reinhold, 2012, CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set, Cancer Res., 72, 3499, 10.1158/0008-5472.CAN-12-1370 · DOI · Paper page
  30. Shoemaker, 2006, The NCI60 human tumour cell line anticancer drug screen, Nat. Rev. Cancer, 6, 813, 10.1038/nrc1951 · DOI · Paper page
  31. Suad, 2009, Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations, J. Mol. Biol., 385, 249, 10.1016/j.jmb.2008.10.063 · DOI · Paper page
  32. Vagin, 2004, REFMAC5 dictionary: organization of prior chemical knowledge and guidelines for its use, Acta Crystallogr. D Biol. Crystallogr., 60, 2184, 10.1107/S0907444904023510 · DOI · Paper page
  33. Wang, 2015, Randomized clinical control study of locoregional therapy combined with arsenic trioxide for the treatment of hepatocellular carcinoma, Cancer, 121, 2917, 10.1002/cncr.29456 · DOI
  34. Wang, 2017, The synergistic antitumor effect of arsenic trioxide combined with cytotoxic T cells in pulmonary metastasis model of colon cancer, Oncotarget, 8, 109609, 10.18632/oncotarget.22757 · DOI
  35. Wang, 2001, The 'wildtype' conformation of p53: epitope mapping using hybrid proteins, Oncogene, 20, 2318, 10.1038/sj.onc.1204316 · DOI
  36. Wang, 2008, Acute promyelocytic leukemia: from highly fatal to highly curable, Blood, 111, 2505, 10.1182/blood-2007-07-102798 · DOI · Paper page
  37. Wilcken, 2012, Kinetic mechanism of p53 oncogenic mutant aggregation and its inhibition, Proc. Natl. Acad. Sci. U S A, 109, 13584, 10.1073/pnas.1211550109 · DOI · Paper page
  38. Williams, 2018, MolProbity: more and better reference data for improved all-atom structure validation, Protein Sci., 27, 293, 10.1002/pro.3330 · DOI · Paper page
  39. Yan, 2014, Arsenic trioxide reactivates proteasome-dependent degradation of mutant p53 protein in cancer cells in part via enhanced expression of Pirh2 E3 ligase, PLoS One, 9, e103497, 10.1371/journal.pone.0103497 · DOI
  40. Yan, 2011, Mutant p53 protein is targeted by arsenic for degradation and plays a role in arsenic-mediated growth suppression, J. Biol. Chem., 286, 17478, 10.1074/jbc.M111.231639 · DOI
  41. Yap, 2004, Ser392 phosphorylation regulates the oncogenic function of mutant p53, Cancer Res., 64, 4749, 10.1158/0008-5472.CAN-1305-2 · DOI
  42. Yu, 2012, Allele-specific p53 mutant reactivation, Cancer Cell, 21, 614, 10.1016/j.ccr.2012.03.042 · DOI · Paper page
  43. Zhang, 2018, APR-246 reactivates mutant p53 by targeting cysteines 124 and 277, Cell Death Dis., 9, 439, 10.1038/s41419-018-0463-7 · DOI · Paper page
  44. Zhang, 2010, Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML, Science, 328, 240, 10.1126/science.1183424 · DOI · Paper page
  45. Zhu, 2013, Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial, J. Clin. Oncol., 31, 4215, 10.1200/JCO.2013.48.8312 · DOI · Paper page

Cited by

See all 241

Metadata

Authors
Chen, S., Wu, J.-L., Liang, Y., Tang, Y.-G., Song, H.-X., Wu, L.-L., Xing, Y.-F., Yan, N., Li, Y.-T., Wang, Z.-Y., Xiao, S.-J., Lu, X., Chen, S.-J., & Lu, M.
Venue
Cancer Cell
Publisher
Elsevier BV
Published
2021-02
Volume
39
Issue
2
Pages
225-239.e8
ISSN
1535-6108
DOI
10.1016/j.ccell.2020.11.013
Cited by
241
References
15
Language
en
Update notices
erratum (2025-08-11)
Licence
Funders
  • Program of Shanghai Academic Research Leader (20XD1422700)
  • National Key Research and Development Program of China (2017YFA0506200)
  • National Natural Science Foundation of China (2018CR006, 81861130368, 82073292, 81622002)
  • Shanghai Municipal Education Commission
  • Ludwig Institute for Cancer Research

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Arsenic Trioxide Rescues Structural p53 Mutations through a Cryptic Allosteric Site. https://app.cochat.ai/papers/10.1016/j.ccell.2020.11.013
The paper
Chen, S., Wu, J.-L., Liang, Y., Tang, Y.-G., Song, H.-X., Wu, L.-L., Xing, Y.-F., Yan, N., Li, Y.-T., Wang, Z.-Y., Xiao, S.-J., Lu, X., Chen, S.-J., & Lu, M. (2021). Arsenic Trioxide Rescues Structural p53 Mutations through a Cryptic Allosteric Site. Cancer Cell. https://doi.org/10.1016/j.ccell.2020.11.013

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.